Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Akcea Therapeutics Inc
(NQ:
AKCA
)
18.17
USD
UNCHANGED
Last Price
Updated: 5:44 PM EDT, Oct 9, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Akcea Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
October 30, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI,...
From
PR Newswire
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
October 12, 2020
Transaction creates a stronger, more efficient company
From
PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
September 26, 2020
Halper Sadeh LLP, a global investor rights law firm, is investigating:
From
PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
September 25, 2020
From
PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (N
September 25, 2020
From
PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm – CGIX, BYFC, BMCH, AKCA
September 23, 2020
From
ACCESSWIRE
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
September 22, 2020
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to...
From
PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU
September 21, 2020
From
ACCESSWIRE
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc
September 16, 2020
From
GlobeNewswire News Releases
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – AIMT, AKCA, PTI
September 12, 2020
From
ACCESSWIRE
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA
September 12, 2020
Halper Sadeh LLP, a global investor rights law firm, is investigating:
From
Business Wire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations
September 11, 2020
From
PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer G
September 10, 2020
From
PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN
September 10, 2020
Halper Sadeh LLP, a global investor rights law firm, is investigating:
From
PR Newswire
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm
September 05, 2020
Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc. ("Akcea") (NASDAQ: AKCA) on behalf of the company's shareholders.
From
PR Newswire
AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA
September 04, 2020
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to...
From
Business Wire News Releases
Stocks Trading Above 20Days Moving Average: $VRA $JNCE $AKCA
September 03, 2020
Tags
The Market Signal
From
The Market Signal
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA
September 01, 2020
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics,...
From
PR Newswire
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?
September 01, 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Akcea Therapeutics, Inc. (NASDAQ: AKCA) ("Akcea" or the "Company") breached their...
From
PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.
August 31, 2020
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA" or the "Company") (NASDAQ: AKCA) in...
From
PR Newswire
AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm
August 31, 2020
From
GlobeNewswire News Releases
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
August 31, 2020
- Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
From
PR Newswire
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
August 29, 2020
Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to...
From
PR Newswire
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
August 29, 2020
Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic...
From
PR Newswire
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
August 24, 2020
Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
From
PR Newswire
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
August 18, 2020
Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease
From
PR Newswire
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
August 13, 2020
WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe
From
PR Newswire
Akcea Reports Financial Results and Highlights for Second Quarter 2020
August 04, 2020
Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year
From
PR Newswire
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
July 22, 2020
TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection
From
PR Newswire
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
July 21, 2020
Webcast scheduled for Tuesday, August 4 at 4:30 p.m. Eastern Time
From
PR Newswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password